Tisdag 21 Januari | 23:33:05 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-11-12 07:00 Kvartalsrapport 2025-Q3
2025-08-21 07:00 Kvartalsrapport 2025-Q2
2025-05-15 07:00 Kvartalsrapport 2025-Q1
2025-04-25 N/A Årsstämma
2025-02-20 08:00 Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-10-01 - Split LIFE 13:1
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - Extra Bolagsstämma 2024
2024-05-08 - Kvartalsrapport 2024-Q1
2024-05-02 - X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-05-08 - X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-09 - X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 - Årsstämma
2022-04-21 - Bokslutskommuniké 2021
2021-09-30 - Extra Bolagsstämma 2021
2021-08-05 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 - Årsstämma
2021-04-20 - Bokslutskommuniké 2020
2020-06-26 - Årsstämma
2020-06-01 - Bokslutskommuniké 2019
2019-02-07 - Split LIFE 4:1
2018-12-11 - Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2024-08-21 07:00:00

Bergen, Norway, 21 August 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can announce positive results from nine weeks of sensor longevity trials.

Reference is made to press releases 18 June 2024 when the company initiated the trials with wireless readout. The Sencell sensor that has been implanted under the skin of the dog Elli has now passed an operational lifetime of two months and still counting. During these months, the Lifecare Veterinary team located at the Norwegian University of Life Sciences (NMBU) has received large amounts of data. This validates the functionality of the Sencell sensor and the sensor technology itself.

The main purpose of the first sensor of the longevity trial is to investigate and confirm operational lifetime in a longevity perspective. In this context, the primary expectations of the study are to confirm the longevity of the physical sensor properties, and that the sensor biocompatibility ensures that no negative body reactions occur in a longevity perspective. The Team at Lifecare Veterinary monitors the first pet-patient Elli on a daily basis, including reports from her owner. Elli is in good health and shows no signs of discomfort related to the implant.

- We are very excited to conclude two months of sensor longevity under Elli's skin. The results from the study, which has been ongoing throughout the summer, is in line with what we expected. However, it is very encouraging to achieve the positive results of longevity in real-world settings. As we have passed two months of operational lifetime, based on a wireless readout, we are proud to conclude that the initial part of the longevity study is a success, says CEO Joacim Holter at Lifecare.

- Previous in-vitro studies have confirmed sensor lifetime of six months. With this initial conclusion of more than 9 weeks operational lifetime in vivo – in real life settings – we exceed the operational lifetime of all the major CGM systems in the market with a factor of 4,5 or more. This is, of course, interesting in a future commercial perspective, says Holter

- Alongside the initial part of the longevity study, we are preparing to enroll additional patients in the study to confirm these first results, and to intensify the study beyond sensor functionality, focusing sharper on glucose readings from both healthy dogs and dogs with diabetes. With this approach we expect to gain increased understanding of the sensor functionality in real life conditions, says Managing Director Jo Amundstad at Lifecare Veterinary.

The approved study protocol allows us to implant the Sencell for a period of 12 weeks, after which it will be removed and specific studies on the potential tissue impact will be evaluated. Due to the encouraging course of this initial part of the study, we are currently in dialog with the regulatory authorities to increase the implant period to 24 or more weeks before removal, says Amundstad.